Compare GPMT & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | ITRM |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.9M | 24.3M |
| IPO Year | N/A | 2018 |
| Metric | GPMT | ITRM |
|---|---|---|
| Price | $1.50 | $0.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.00 | ★ $9.00 |
| AVG Volume (30 Days) | 159.7K | ★ 1.1M |
| Earning Date | 05-05-2026 | 03-20-2026 |
| Dividend Yield | ★ 13.33% | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $422.75 | N/A |
| Revenue Next Year | $34.54 | $947.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $0.14 |
| 52 Week High | $3.12 | $1.42 |
| Indicator | GPMT | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 24.49 | 37.57 |
| Support Level | N/A | $0.14 |
| Resistance Level | $1.83 | $0.39 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 10.79 | 21.79 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the property.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.